These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8900332)

  • 1. Pathogenic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis.
    Ganz P; Creager MA; Fang JC; McConnell MV; Lee RT; Libby P; Selwyn AP
    Am J Med; 1996 Oct; 101(4A):4A10S-16S. PubMed ID: 8900332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipid lowering therapy: new pathophysiologic aspects and clinical implications].
    Nordmann A; Martina B; Keller U; Battegay E
    Schweiz Med Wochenschr; 1998 Apr; 128(17):665-70. PubMed ID: 9622839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
    De Caterina R; Lenzi S
    G Ital Cardiol; 1998 Feb; 28(2):168-77. PubMed ID: 9534058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid lowering therapy and stabilization of atherosclerotic plaques.
    Krone W; Müller-Wieland D
    Thromb Haemost; 1999 Sep; 82 Suppl 1():60-1. PubMed ID: 10695487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive lipid-lowering therapy: a clinical imperative.
    Pedersen TR
    Eur Heart J; 1998 Oct; 19 Suppl M():M15-21. PubMed ID: 9821012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease.
    van der Harst P; Wagenaar LJ; Buikema H; Voors AA; Plokker HW; Morshuis WJ; Six AJ; Boonstra PW; Nickenig G; Wassmann S; van Veldhuisen DJ; van Gilst WH
    Am J Cardiol; 2005 Nov; 96(10):1361-4. PubMed ID: 16275178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is regression of atherosclerosis possible?].
    Thomas D; Richard JL; Emmerich J; Bruckert E; Delahaye F
    Arch Mal Coeur Vaiss; 1992 Oct; 85 Spec No 3():47-57. PubMed ID: 1296545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atherosclerosis and simvastatin: new questions for the new millennium].
    Tubaro M; Guido V; Sciarra L; Mustilli M; Carbone MA; D'Errico F
    Ann Ital Med Int; 2000; 15(1):108-14. PubMed ID: 10842900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of statins in reversing atherosclerosis: what the latest regression studies show.
    Grines CL
    J Interv Cardiol; 2006 Feb; 19(1):3-9. PubMed ID: 16483333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Med; 2005 Dec; 118 Suppl 12A():22-7. PubMed ID: 16356804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of lipid lowering measures on coronary perfusion].
    Steinmetz A; Maisch B; Noll B
    Z Kardiol; 1997; 86 Suppl 1():43-55. PubMed ID: 9173721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial function and coronary risk reduction: mechanisms and influences of nitric oxide.
    Fair JM; Berra K
    Cardiovasc Nurs; 1996; 32(3):17-22. PubMed ID: 8697489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reduction of coronary events: what are the possible mechanisms?].
    Badimón L; Pueyo Palazón C; Varela Villén O; Viñals Izquierdo M
    Rev Esp Cardiol; 1995; 48 Suppl 2():18-22. PubMed ID: 7569271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The relationship between clinical events and the angiographic lesions in coronary atherosclerosis. Hypolipemic treatment and plaque stabilization].
    Castro Beiras A; Vázquez Rodríguez JM; Muñiz J; Calviño R; Vázquez González N; Juane R
    Rev Esp Cardiol; 1995; 48 Suppl 5():23-30. PubMed ID: 7494936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease.
    Selwyn AP; Kinlay S; Creager M; Libby P; Ganz P
    Am J Cardiol; 1997 Mar; 79(5A):17-23. PubMed ID: 9127617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of trials on regression of atheromatous lesions with hypolipemic drugs].
    Coste P; Durrieu C; Besse P
    Arch Mal Coeur Vaiss; 1992 Sep; 85 Spec No 2():189-94. PubMed ID: 1285702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in atherosclerosis.
    Spence JD
    Baillieres Clin Neurol; 1995 Aug; 4(2):191-205. PubMed ID: 7496617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of atherosclerosis: which components regress and what influences their reversal.
    Kramsch DM; Blankenhorn DH
    Wien Klin Wochenschr; 1992; 104(1):2-9. PubMed ID: 1546480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.